BiomX Inc. - Common Stock, $0.0001 par value per share (PHGE)

CUSIP: 09090D103

Q3 2025 13F Holders as of 30 Sep 2025

Holder snapshot 3 signals
Share change
0
SEC-reported price per share
$0.52
Number of holders
2
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
11,618,400

Security key

09090D103

Report period

Q3 2025

Institutions

2

Top holders

2

Ownership snapshot

Top reported holders of PHGE - BiomX Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Nantahala Capital Managem...
Disclosed value leader
OrbiMed Israel BioFund GP...
Comparable rows
3/15
Latest evidence
30 Jun 2025
13D/G 13F 3/4/5 Lead comparable stake: 10% 12 rows are not safely comparable across share classes. 13D/G row: Nantahala Capital Management, LLC Showing 1-6 of 15 holder rows.

Quick read

Nantahala Capital Management, LLC leads the comparable SEC ownership view at 10%.

3 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Nantahala Capital Management, LLC's linked filing trail.
Comparable ownership Top 3
Nantahala Capital Management, LLC 10%
Centaurus Investments Ltd 7.6%
OrbiMed Israel BioFund GP Limited... 1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Nantahala Capital Management, LLC
13D/G 13F
Company
10%
Reported 13D/G · 31 Mar 2025
$1,496,518
2,494,197 shares
+$420,034 31 Mar 2025
Centaurus Investments Ltd
13D/G
Rodney Hodges
7.6%
Reported 13D/G · 21 Apr 2025
$1,182,242
1,970,403 shares
$0 21 Apr 2025
OrbiMed Israel BioFund GP Limited Partnership
3/4/5 13D/G
10%+ Owner · ORBIMED ISRAEL GP LTD.
1%
Reported 13D/G · 18 Jun 2025
$5,250,517
13,777,980 shares
mixed-class rows
— 15 May 2024
Cystic Fibrosis Foundation
3/4/5
10%+ Owner
—
mixed-class rows
$1,663,688
11,131,426 shares
mixed-class rows
— 26 Feb 2025
Ugwumba Chidozie
3/4/5
Exit Form 4 - former 10% owner
—
denominator unverified
$1,018,989
2,997,025 shares
— 17 Oct 2022
James E. Flynn
3/4/5
Director, *Director by Deputization
—
mixed-class rows
$2,321,016
5,831,350 shares
mixed-class rows
— 21 Apr 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
2
Shares
97,025
Rows available
2
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2025 vs Q3 2025 Across Filers

Q3 2025 holders
2
Q3 2025 holders
2
Holder diff
0
Investor Q3 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q3 2025 value Q3 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .